Clinical Information

Further Information by Specialty:

Featured Video Case

FLOSEAL

Use on
heparinised
CABG patient.

Newsletter Subscription

Newsletter Subscription

Receive

Solutions in
Haemostasis
article series.

Sign Up Now

CLINICAL INFORMATION – CARDIOVASCULAR

Essential Tool to Control Bleeding
in Cardiovascular Surgery*

Fast and effective haemostasis

  • Stops bleeding fast#,1
  • More than 5 minutes faster median time to haemostasis than GELFOAM with thrombin1
  • Can be applied to wet actively bleeding tissue or pooled blood sites2
  • Only haemostatic agent proven effective on all degrees of bleeding from oozing to spurting3,4
  • Rate of transfusion of blood products was statistically decreased in the FLOSEAL group (p < 0.001 both) compared to alternative topical haemostatic agents5

FLOSEAL effective in heparinised patients, Reduced rate transfusion with FLOSEAL

*When control of bleeding by ligature or conventional procedures is ineffective or impractical.
# Median time to haemostasis in cardiac patient cohort was 2.8 minutes. Median time to stop bleeding across all surgical specialties was 2 minutes.

  1. Oz MC, Rondinone JF, Shargill NS. Floseal matrix: new generation topical hemostatic sealant. J Card Surg. 2003;18:486-93.
  2. Floseal VH S/D Hemostatic Matrix [instructions for use]. Zurich, Switzerland: Baxter Healthcare SA; 2009.
  3. Data on file. Deerfield, Ill: Baxter International Inc.
  4. Oz MC, Cosgrove DM, Badduke BR. Controlled clinical trial of a novel hemostatic agent in cardiac surgery. Ann Thorac Surg. 2000;69:1376-82.
  5. Nasso G, Piancone F, Bonifazi R, et al. Prospective, randomized clinical trial of the FloSeal matrix sealant in cardiac surgery. Ann Thorac Surg. 2009;88:1520-26.